AGRUF yields 4.25% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 8
Combined, AGRUF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of AGRUF + JNJ for your $10,000?
AF Gruppen ASA, a contracting and industrial company, engages in civil engineering, construction, property, energy, environment, and offshore businesses primarily in Norway and Sweden. The company's Civil Engineering business area undertakes civil engineering and niche projects related to roads and railways, port facilities, airports, tunnels, foundation work, power, and energy, as well as onshore facilities for oil and gas. Its Construction business area develops, engineers, and constructs commercial, residential, and public buildings, as well as rehabilitation projects. The company's Betonmast business area operates as building contractor for large residential properties, and commercial and public buildings; and develops properties. Its Property business area develops residential units and commercial buildings. The company's Energy and Environment business area provides smart and energy efficient services for buildings and industry; and demolition and recycling services. Its Sweden business area engages in construction, civil engineering, property, and environmental activities. The company's offshore business area undertakes the removal, demolition, and recycling of offshore installations; and construction, modification, and maintenance works related to cranes, modules, and rig services, as well as heating, ventilation, air conditioning, and cooling systems. AF Gruppen ASA was founded in 1985 and is headquartered in Oslo, Norway.
Full AGRUF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.